Tocilizumab and Cutaneous Vasculitis: A Drug Safety Signal from WHO-UMC

This is the third drug safety signal – “Cutaneous Vasculitis association with Tocilizumab use” detected from the VigiBase by the UMC (Uppsala Monitoring Center). UMC is a WHO Collaborating Centre present in Sweden for international service and scientific research within the field of pharmacovigilance. Tocilizumab is an immunosuppressive agent and a biologic medication (fully human

Alectinib – Rhabdomyolysis: A Drug Safety Signal from WHO-UMC’s VigiBase Database

A new drug safety signal- “Rhabdomyolysis association with Alectinib” identified by the UMC (Uppsala Monitoring Center), from the VigiBase, a global drug safety database maintained by UMC on behalf of WHO. UMC is a WHO Collaborating Centre present in in Sweden for international service and scientific research within the field of pharmacovigilance. Alectinib is an

Drug Safety Signal from WHO-UMC: Acyclovir or valaciclovir – Acute generalised exanthematous pustulosis

A new drug safety signal “Acyclovir or valaciclovir – Acute generalised exanthematous pustulosis”, identified by the UMC (Uppsala Monitoring Center), a WHO Collaborating Centre for international service and scientific research within the field of pharmacovigilance. This drug safety signal is identified from the VigiBase, a global drug safety database maintained by UMC on behalf of

A signal of cardiac arrhythmias with the use of Ginkgo biloba L.

A new drug safety signal from UMC: Cardiac arrhythmia with the use of Ginkgo biloba L.

WHO-Uppsala Monitoring Center (UMC) identified a new drug safety signal-“cardiac arrhythmias-Ginkgo biloba“ from the VigiBase, a global drug safety database maintained by UMC on behalf of WHO for international service and scientific research within the field of pharmacovigilance. In the month of July-2020, WHO-UMC has identified and released two new drug safety signals. Drug Safety

A new drug safety signal from Uppsala Monitoring Centre (UMC) Lack of drug dose titration (Medication error) during treatment with clozapine

A New Drug Safety Signal from Uppsala Monitoring Centre (UMC): Lack of drug dose titration (Medication error) during treatment with clozapine

A new drug safety signal identified by the Uppsala Monitoring Centre (UMC), Sweden a WHO Collaborating Centre for international service and scientific research within the field of pharmacovigilance. This safety signal is identified from the VigiBase, a global drug safety database maintained by UMC on behalf of WHO and published in the WHO Pharmaceuticals newsletter

Risk of Increased Blood Pressure with Agomelatine (An Antidepressant Drug)

A new drug safety signal was triggered from the WHO’s global drug safety database for pharmacovigilance activities. This signal was identified by the UMC (Uppsala Monitoring Center), a WHO Collaborating Centre for international service and scientific research within the field of pharmacovigilance. Agomelatine Agomelatine is an atypical antidepressant medication used to treat major depressive disorder.

error: Content is protected !!